Skip to main content

Vorinostat

Names

Zolinza® Vorinostat

Indications and usage

Vorinostat is FDA approved to treat cutaneous T-cell lymphoma (CTCL) in patients whose CTCL gets worse, does not go away or comes back after treatment with two systemic therapies.

Side effects needing medical attention

Blood clots in the legs (deep vein thrombosis); sudden swelling in a leg; pain or tenderness in the leg (the pain may only be felt when standing or walking); increased warmth in the area where the swelling is; skin redness or change in skin color; sudden, sharp chest pain; rapid pulse; fainting; cough with bloody secretions; feeling anxious; sweating; dehydration (loss of too much fluid from the body); low red blood cells; unusual bleeding or bruising under the skin; high blood sugar; paleness, shortness of breath and unusual tiredness. 

The Leukemia & Lymphoma Society (LLS) is now Blood Cancer United. Learn more.